SBP GROUP (01177) rose over 4%, up 3.95% at the time of writing, trading at HK$5 with a turnover of HK$428 million. On May 29, SBP GROUP announced that Bepirovirsen, co-developed by its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with GlaxoSmithKline PLC (GSK), has released positive pivotal data for treating chronic hepatitis B (CHB). Results from two Phase III clinical trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), were simultaneously published in the New England Journal of Medicine and will be presented at the 2026 European Association for the Study of the Liver (EASL) congress. Regional subgroup data were also presented in an oral report at EASL. The Chinese subgroup data showed a functional cure rate of 24% in subjects with HBsAg ≤3000 IU/ml, and 35% in those with HBsAg ≤1000 IU/ml. Bepirovirsen is currently under review by regulatory authorities in China (where it has been included in breakthrough therapy and priority review programs), the United States (having received priority review, breakthrough therapy, and fast track designations), Europe, and Japan (having received SENKU designation). GSK anticipates receiving a regulatory decision from China's National Medical Products Administration in the first half of 2027, with launch preparations currently underway.
SBP GROUP (01177) rose over 4%, up 3.95% at the time of writing, trading at HK$5 with a turnover of HK$428 million. On May 29, SBP GROUP announced that Bepirovirsen, co-developed by its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with GlaxoSmithKline PLC (GSK), has released positive pivotal data for treating chronic hepatitis B (CHB). Results from two Phase III clinical trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), were simultaneously published in the New England Journal of Medicine and will be presented at the 2026 European Association for the Study of the Liver (EASL) congress. Regional subgroup data were also presented in an oral report at EASL. The Chinese subgroup data showed a functional cure rate of 24% in subjects with HBsAg ≤3000 IU/ml, and 35% in those with HBsAg ≤1000 IU/ml. Bepirovirsen is currently under review by regulatory authorities in China (where it has been included in breakthrough therapy and priority review programs), the United States (having received priority review, breakthrough therapy, and fast track designations), Europe, and Japan (having received SENKU designation). GSK anticipates receiving a regulatory decision from China's National Medical Products Administration in the first half of 2027, with launch preparations currently underway.
Comments